Tuesday, October 20, 2026 · Five AI analysts screened this index for stocks with the best shot at gaining +5% within 30 days
Neutral Normal choppiness · VIX 17.4
This looks like the heart of Q3 earnings season, with extreme dispersion rather than a clean directional trend: large-cap tech, semiconductors, and several banks are selling off sharply (INTC, AMAT, KLAC, AMD, BAC, MS, SCHW all down double digits over 5 days), while healthcare (especially managed care and distributors), energy, and payments names are pushing to or near 52-week highs on sustained 5- and 30-day momentum. The setup favors selective, catalyst-driven longs in the strongest pockets rather than broad index exposure.
Which of today's picks to actually take, and at what size, given what you are already holding. Each pick's own Suggested Allocation sizes it in isolation; this table applies the portfolio limits — at most 20 open positions and 60% of the portfolio committed in total. Run with --capital 25000 to see these sizes as order amounts rather than percentages.
| Rank | Stock | Action | Size | Entry → Target | Notes |
|---|---|---|---|---|---|
| #1 | PFE | SKIP | — | $30.25 → $31.92 stop $28.13 |
Half-Kelly sizes this at 0% — the odds carry no edge worth capital. |
| #2 | CVX | SKIP | — | $224.82 → $236.44 stop $212.90 |
Position cap reached — 70 of 20 slots in use. |
| #3 | SPGI | SKIP | — | $437.18 → $459.04 stop $419.26 |
Position cap reached — 70 of 20 slots in use. |
| #4 | COR | SKIP | — | $342.43 → $359.55 stop $328.39 |
Position cap reached — 70 of 20 slots in use. |
Already open: LGEN.L (to Oct 21), SSE.L (to Oct 21), AAPL (to Oct 22), KGF.L (to Oct 23), DHR (to Oct 24), DCC.L (to Oct 25), DPLM.L (to Oct 28), ABDN.L (to Oct 30), EMR (to Nov 1), ALW.L (to Nov 1), PSN.L (to Nov 1), MSFT (to Nov 4) … and 58 more. Symbols you already hold were excluded from this run's candidates rather than re-picked.
Position-sizing guidance only — half-Kelly per pick, bounded by the limits above. Not personal investment advice.
Pfizer is one of the world's largest pharmaceutical companies, known for vaccines and a broad medicine portfolio. It just raised its full-year sales forecast, and its own CEO plus two board members recently bought shares with their own money — a strong vote of confidence. The main risk is that the stock has already climbed quickly and has another earnings report due within the 30-day window, which could swing the price either way.
Why the AI likes it
What could go wrong
Calibrated probability: 55% (raw model estimate: 64%) — adjusted using the accuracy of past resolved picks.
Trade math
Suggested allocation is half-Kelly sizing guidance capped at 10% — not personal investment advice. Allocations are scaled to 85% of half-Kelly for the current market regime.
What each AI analyst estimated
Chevron is one of the world's biggest oil and gas producers. Its stock has been climbing steadily and outperforming the broader market, helped by strength across the energy sector right now. The main risk is that energy stocks are tied to oil prices, which can swing quickly, and the company reports earnings in 10 days which adds uncertainty.
Why the AI likes it
What could go wrong
Calibrated probability: 55% (raw model estimate: 66%) — adjusted using the accuracy of past resolved picks.
Trade math
Suggested allocation is half-Kelly sizing guidance capped at 10% — not personal investment advice. Allocations are scaled to 85% of half-Kelly for the current market regime.
What each AI analyst estimated
S&P Global provides credit ratings and financial data that Wall Street relies on every day. Its stock has bounced back strongly and is beating the overall market, though it's still well below its old highs. The key risk is an earnings report in just a week, especially since the company missed estimates last quarter.
Why the AI likes it
What could go wrong
Calibrated probability: 55% (raw model estimate: 65%) — adjusted using the accuracy of past resolved picks.
Trade math
Suggested allocation is half-Kelly sizing guidance capped at 10% — not personal investment advice. Allocations are scaled to 85% of half-Kelly for the current market regime.
What each AI analyst estimated
Cencora is a major distributor of pharmaceuticals and medical products to hospitals and pharmacies. The stock has had a strong, steady climb and is beating the broader market, part of a wider rally in healthcare distribution names. The main risk is an earnings report landing within the holding period that could shake up the stock either way.
Why the AI likes it
What could go wrong
Calibrated probability: 55% (raw model estimate: 63%) — adjusted using the accuracy of past resolved picks.
Trade math
Suggested allocation is half-Kelly sizing guidance capped at 10% — not personal investment advice. Allocations are scaled to 85% of half-Kelly for the current market regime.
What each AI analyst estimated
This report identifies stocks with an AI-assessed probability of gaining +5% within 30 calendar days (target exit by November 19, 2026). Picks are ranked by how many independent AI agents agreed — more agreement means higher conviction. The guide below tells you exactly how to act on them.
Step-by-Step Action Plan
Position Sizing by Conviction Tier
Size each position according to the coloured border on its pick card. Cap your total exposure across all picks from this report at 25% of your overall trading budget.
| Agents Agreeing | What It Means | Max Allocation Per Pick |
|---|---|---|
| 5/5 | Highest conviction — all five independent analytical checks passed | Up to 10% |
| 4/5 | Very high conviction — four of five independent checks aligned | Up to 8% |
| 3/5 | High conviction — three agents independently agreed | Up to 6% |
| 2/5 | Moderate conviction — two agents independently agreed | Up to 4% |
| 1 Agent | Speculative — solo pick, admitted only at Very High confidence | Up to 2% |
The Three Exit Rules
A plain-English guide to every figure shown on each pick card — what it means, how it is calculated, and what a good or bad value looks like.
Scout scanned 503 S&P 500 constituents and short-listed 28 candidates for deep analysis by the five analysts. Here is what happened to each one.
Checks 30-day price history for every candidate before making any selection. Requires positive period return and positive 5-day momentum as mandatory gates. Ranks picks by proximity to their period high and adjusts probability based on volume. Uses news only to rule out major negative catalysts.
Searches earnings results, analyst upgrades, and revenue trends before checking price data. Requires at least one verifiable fundamental catalyst — earnings beat, analyst upgrade, or revenue acceleration — within the last 60 days. Favours stocks with strong fundamentals trading below recent highs (value entry).
Hunts for specific events within the last 21 days: FDA approvals, major contract wins, product launches, earnings surprises, or significant analyst upgrades. Requires a positive price reaction confirming the market is recognising the catalyst. Also scans for upcoming events that could drive further gains.
Maps the macroeconomic regime (risk-on / risk-off / neutral) and identifies sectors benefiting from current conditions before looking at individual stocks. Only selects stocks from macro-aligned sectors with confirmed sector tailwinds. Adjusts for interest rate sensitivity and geopolitical factors.
Reviews the final picks after all four analysts agree and actively challenges each bull thesis. Searches for bearish technical signals, negative news, insider selling, and elevated short interest that the agreeing agents may have underweighted. Produces evidence-based counter-arguments shown on each pick card.
Pure-quant analyst: no news, no narrative, only numbers. Identifies mean-reversion setups from RSI extremes (<35) with momentum turning, Bollinger squeeze breakouts, and multi-factor quant scores using RSI, MACD, OBV, short interest, and insider transaction data. Counterbalances narrative bias across the four analyst agents.